Avastin licence extended in metastatic breast cancer

Bevacizumab is also licensed for colorectal, lung and renal cancer
Bevacizumab is also licensed for colorectal, lung and renal cancer
The licensed use of bevacizumab (Avastin) for the treatment of metastatic breast cancer has been broadened to include use in combination with capecitabine when taxanes or anthracyclines are not appropriate. Patients who have received taxane and anthracycline-containing regimens should not receive bevacizumab in combination with capecitabine.

Use of bevacizumab with capecitabine was evaluated in the multicentre, placebo-controlled, phase 3 RIBBON-1 study in patients with HER2-negative metastatic or locally recurrent breast cancer. Patients (n=1237) were randomised to receive chemotherapy plus bevacizumab or chemotherapy plus placebo every 3 weeks. Chemotherapy options included capecitabine, a taxane and anthracycline-based agents.

For statistical analysis, patients were divided into 2 cohorts defined by chemotherapy received. The primary endpoint, median progression-free survival, was longer for capecitabine plus bevacizumab than for capecitabine plus placebo: 8.6 months vs 5.7 months, with a hazard ratio of 0.69 (95% CI 0.56-0.84; p<0.001).


Read these next

Avastin licensed for ovarian, fallopian tube and peritoneal cancers

Avastin licensed for ovarian, fallopian tube and peritoneal cancers

Bevacizumab (Avastin) is now indicated in combination...


Have you registered with us yet?

Register now to enjoy more articles and free email bulletins

Register
Already registered?
Sign in

Register or Subscribe to MIMS

GPs can get MIMS print & online and GPonline for free when they register online – take 2 minutes, and make sure you get your free MIMS access! If you're not a GP, you can subscribe to MIMS for full access.

Register or subscribe

MIMS bulletins

News and updates straight to your inbox.

Prescribing Update: Fortnightly news bulletin
Alert:
Urgent prescribing updates
Spotlight: Disease-themed monthly round-up

Sign me up

MIMS Dermatology

Read the latest issue online exclusively on MIMS Learning.

Read MIMS Dermatology

MIMS Adviser

Especially created for prescribing influencers.

Request free copy

Mobile apps

MIMS: access the full drug database and quick-reference tables on the go

MIMS Diagnosis and Management: concise information on signs and symptoms, investigations and diseases